OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0522 0.00 (0.00 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$0.0522
Today's Range$0.0520 - $0.0590
52-Week Range$0.05 - $0.21
Volume849,975 shs
Average Volume942,429 shs
Market Capitalization$12.24 million
P/E Ratio-1.31
Dividend YieldN/A
Beta3.69
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INNV
Previous SymbolNASDAQ:INNV
CUSIPN/A
Phone858-964-5123

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.82 million
Book Value$0.01 per share

Profitability

Net Income$-6,500,000.00

Miscellaneous

Employees12
Market Cap$12.24 million
OptionableNot Optionable

Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) issued its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.00. The firm had revenue of $7.38 million for the quarter, compared to the consensus estimate of $7.65 million. Innovus Pharmaceuticals had a negative net margin of 35.23% and a negative return on equity of 517.44%. View Innovus Pharmaceuticals' Earnings History.

When is Innovus Pharmaceuticals' next earnings date?

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Innovus Pharmaceuticals.

Has Innovus Pharmaceuticals been receiving favorable news coverage?

News stories about INNV stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of Innovus Pharmaceuticals' key competitors?

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the folowing people:
  • Dr. Bassam B. Damaj, Pres, CEO & Director (Age 50)
  • Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 57)
  • Mr. Ryan J. Selhorn CPA, VP & CFO (Age 36)
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $0.0522.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $12.24 million and generates $8.82 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis. Innovus Pharmaceuticals employs 12 workers across the globe.

What is Innovus Pharmaceuticals' official website?

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]


MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel